Johnson & Johnson vs Ultragenyx Pharmaceutical Inc. — Stock Comparison
Johnson & Johnson (JNJ) and Ultragenyx Pharmaceutical Inc. (RARE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson clearly outscores Ultragenyx Pharmaceutical Inc. on Q·Score (7.1 vs 5.4 out of 10), led by Quality (9.3 vs 2.2) and Growth (5.1 vs 3.4). Ultragenyx Pharmaceutical Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for RARE (+89.7%) than for JNJ (+10.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Consensus analyst target of $52.05 is 90% above current price.
⚠ currently unprofitable (-91% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs RARE: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Ultragenyx Pharmaceutical Inc. (RARE) at 5.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or RARE?
Johnson & Johnson (JNJ) scores higher on Growth (5.1/10 vs 3.4/10). Johnson & Johnson reports revenue growth (9.9% YoY) while Ultragenyx Pharmaceutical Inc. reports (-2.2% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or RARE more attractively valued?
Ultragenyx Pharmaceutical Inc. (RARE) scores higher on Valuation (9/10 vs 7.3/10). JNJ trades at 18.0× P/E versus RARE at 28.4×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs RARE?
There are 23 analysts covering JNJ with a consensus price target of $252.87, and 19 analysts covering RARE with a consensus target of $52.05. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or RARE?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 2.2/10). Net profit margin: JNJ at 21.8%, RARE at -90.9%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or RARE?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 5.4/10). Market beta: JNJ at 0.26, RARE at 0.38. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and RARE?
Johnson & Johnson (JNJ) has a market capitalisation of $549.8B, while Ultragenyx Pharmaceutical Inc. (RARE) has a market cap of $2.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →